INDICATIONS

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used with or without MTX.

ENBREL is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.

Close

Easy-to-access ENBREL patient resources that can be shipped to your patient directly or are available as digital downloads to share virtually with your patients. Visit EnbrelResources.com

After ENBREL has been prescribed, this page gives health care professionals (HCPs) access to tools and information that can help patients who have been prescribed ENBREL treatment.

Help Your Patients Get Started With ENBREL

smartphone displaying the Embark® App User Interface

Meet the Embark® App

An app designed to support your patient’s ENBREL experience - all in the palm of their hands. With the app, patients can access financial support information, medication reminders, injection site tracking, and more.

AutoTouch Connect™ Direct Order Form

AutoTouch Connect® Direct Order Form

Complete this form to have an AutoTouch Connect® Autoinjector shipped directly to your patients who have been prescribed the Enbrel Mini® single-dose cartridge.

ENBREL Patient Roadmap ENBREL Patient Roadmap

ENBREL Patient
Roadmap

Give your patients the ENBREL Patient Roadmap—an illustrated guide that helps patients get the support they need to establish a consistent treatment routine.

My ENBREL Guide My ENBREL Guide

My ENBREL Guide

My ENBREL Guide was co-created with patients and developed to help patients navigate the logistics and feelings of uncertainty around starting a biologic as well as address their questions. It can help them to understand how to start treatment and establish a treatment routine, what results they may expect, and help them to understand support services that are available to them.

ENBREL Support® Fax Form ENBREL Support® Fax Form

ENBREL Support® Fax Form

After you have chosen ENBREL, ENBREL Support® is there to support your patients throughout their journey with ENBREL. ENBREL Support® can help your patients start and stay on ENBREL as prescribed. Complete this form to start your patient's enrollment in ENBREL Support®. ENBREL Support® provides information about financial support and supplemental injection support resources.

ENBREL Support® Welcome Videos

ENBREL Support® Welcome Videos

ENBREL Support® is here to provide your patients with resources and information right from the start. We’ve created these videos to help your patients understand how to get started on their prescribed ENBREL, how to get their prescription from the specialty pharmacy, how to administer their injection, their financial support options, and how to track their symptoms and progress.

ENBREL Resources Logo

Ship ENBREL Resources Directly to Your Patients

Easy-to-access ENBREL patient resources that can be direct shipped to your patient or are available for immediate digital download to share virtually.

Alternatively, explore a range of support services, resources, and financial assistance information for your patients.

Learn more at EnbrelSupport.com

In addition to ENBREL Support®, ENBREL has broad coverage and a simplified electronic prior authorization (ePA) option.

Medicare coverage for ENBREL

Medicare coverage

ENBREL is preferred for 99% of Medicare Part D lives1*

Commercial coverage for ENBREL

Commercial coverage

ENBREL is preferred in rheumatoid arthritis and psoriatic arthritis for 83% of commercial lives2*

Simplified electronic prior authorization

Simplified electronic Prior Authorization option

A simplified electronic prior authorization (ePA) solution is available for ENBREL with CoverMyMeds, including live support when needed.

ENBREL electronic prior authorization approvals

55% of ENBREL ePAs submitted through CoverMyMeds receive a determination within one hour, and nearly 85% receive a determination within 24 hours.3†‡

  • * Coverage data as of April 2021.
  • Amgen, the marketer of ENBREL, has entered into a fee-for-service arrangement with CoverMyMeds to provide a simplified ePA experience after you have chosen to prescribe ENBREL. CoverMyMeds is a registered trademark of CoverMyMeds LLC. All rights reserved.
  • Data from June 1, 2021 through June 30, 2022; time between when a complete ePA is submitted to the health plan and determination is received by the HCP.3 These statistics are subject to change and are based upon a multitude of different factors that can influence turnaround time.
ENBREL Nurse Partners

ENBREL Nurse Partners™* are committed to helping your patients who want additional educational support by providing supplemental injection support and helping them establish a treatment routine with ENBREL. Support is available when and where it’s convenient for patients—at home, by phone, or via video chat.

Patients can enroll in the ENBREL Nurse Partners program or speak with an ENBREL Nurse Partner by calling 1-888-4ENBREL (1-888-436-2735).

* ENBREL Nurse Partners™ are nurses by training, but they are not part of a patient’s treatment team or an extension of their doctor’s office. ENBREL Nurse Partners™ will not inject patients with ENBREL. Patients will be referred to their doctor’s office for clinical advice.

Financial Support Options for Your Patients

To find out more about financial support and referral assistance, patients can call 1-888-4ENBREL (1-888-436-2735).

Explore financial support options and referral assistance:

Eligible commercially insured patients may pay as little as $5 per month for ENBREL through the Enbrel® Co-Pay Card Program

Financial Support Options for Your Patients

To find out more about financial support and referral assistance, patients can call 1-888-4ENBREL (1-888-436-2735).

Explore financial support options and referral assistance:

Enbrel® Co-Pay CardEnbrel® Co-Pay Card

Eligible commercially insured patients may pay as little as $5 per month for ENBREL through the Enbrel® Co-Pay Card Program

Commercially Insured Patients

plus-img minus-img

The Enbrel® Co-Pay Card may help your eligible commercially insured patients lower their monthly out-of-pocket prescription costs for ENBREL. *

Patients can confirm their eligibility by visiting EnbrelSupport.com or by calling ENBREL Support® at 1-888-4ENBREL

There is no income requirement for eligibility when it comes to using the Enbrel® Co-Pay Card.

* Subject to eligibility criteria and limitations. For full terms and conditions visit EnbrelSupport.com.

Medicare Solutions

plus-img minus-img
  • Helps Medicare patients understand general Medicare coverage
  • Identifies 3 local Medicare plans that may cover ENBREL
  • Screens patients for Extra Help (LIS) eligibility
  • Provides referral assistance to independent charity patient assistance programs *

* Support provided through independent charitable patient assistance programs and not through ENBREL Support®. Program eligibility is based on the charity's criteria. ENBREL Support® has no control over independent, third-party programs and provides referrals as a courtesy only.

Uninsured and Underinsured Patients

plus-img minus-img

ENBREL Support® can help uninsured and underinsured patients by providing referrals to third-party non-profit foundations *

Patients can call ENBREL Support® at 1-888-4ENBREL

* Provided through independent charitable patient assistance programs; program eligibility is based on the charity’s criteria. Amgen has no control over independent, third-party programs and provides referrals as a courtesy only.

STATWISE™ Self-Reported Symptom Tracker

STATWISETM is a simple-to-use, text message-based program that may help your moderate to severe rheumatoid arthritis and psoriatic arthritis patients see signs of improvement they might be missing. It may help answer their question, "Is ENBREL working for me?" Here is how STATWISETM works to help your patients who sign up:

  • They will be sent 3 text messages every day for 12 weeks asking about key symptoms
  • Your patients will simply respond to each message by rating their symptoms
  • Printed reports will be mailed to your patients every 2 weeks which they can use when they discuss the results with you

Patients can sign up for STATWISETM by visiting www.enbrel.com/resources/statwise-symptom-tracker

Prescription Enbrel® (etanercept) is administered by injection.

IMPORTANT SAFETY INFORMATION AND INDICATIONS

SERIOUS INFECTIONS

Patients treated with ENBREL are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated in the presence of sepsis, active infections, or allergy to ENBREL or its components. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before ENBREL use and periodically during therapy. Treatment for latent infection should be initiated prior to ENBREL use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with ENBREL should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ENBREL, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy.

MALIGNANCIES

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including ENBREL.

In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA patients. The role of TNF blocker therapy in the development of malignancies is unknown.

Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population.

Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including ENBREL. Periodic skin examinations should be considered for all patients at increased risk for skin cancer.

Pediatric Patients

In patients who initiated therapy at ≤18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin's and non-Hodgkin's lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.

NEUROLOGIC REACTIONS

Treatment with TNF-blocking agents, including ENBREL, has been associated with rare (<0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with ENBREL therapy. Prescribers should exercise caution in considering the use of ENBREL in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders.

CONGESTIVE HEART FAILURE

Cases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking ENBREL. Caution should be used when using ENBREL in patients with CHF. These patients should be carefully monitored.

HEMATOLOGIC REACTIONS

Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to ENBREL therapy remains unclear. Exercise caution when considering ENBREL in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ENBREL if significant hematologic abnormalities are confirmed.

HEPATITIS B REACTIVATION

Reactivation of hepatitis B has been reported in patients who were previously infected with hepatitis B virus (HBV) and received concomitant TNF-blocking agents, including ENBREL. Most reports occurred in patients also taking immunosuppressive agents, which may contribute to hepatitis B reactivation. Exercise caution when considering ENBREL in these patients.

ALLERGIC REACTIONS

Allergic reactions associated with administration of ENBREL during clinical trials have been reported in <2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of ENBREL should be discontinued immediately and appropriate therapy initiated.

IMMUNIZATIONS

Live vaccines should not be administered to patients on ENBREL. Pediatric patients, if possible, should be brought up to date with all immunizations prior to initiating ENBREL. In patients with exposure to varicella virus, temporarily discontinue ENBREL and consider prophylactic treatment with Varicella Zoster Immune Globulin.

AUTOIMMUNITY

Autoantibodies may develop with ENBREL, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune hepatitis develops.

USE IN GRANULOMATOSIS WITH POLYANGIITIS PATIENTS

The use of ENBREL in patients with granulomatosis with polyangiitis receiving immunosuppressive agents (eg, cyclophosphamide) is not recommended.

MODERATE TO SEVERE ALCOHOLIC HEPATITIS

Based on a study of patients treated for alcoholic hepatitis, exercise caution when using ENBREL in patients with moderate to severe alcoholic hepatitis.

ADVERSE REACTIONS

The most commonly reported adverse reactions in RA clinical trials were injection site reaction and infection. In clinical trials of all other adult indications, adverse reactions were similar to those reported in RA clinical trials.

In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population.

DRUG INTERACTIONS

The use of ENBREL in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ENBREL and anakinra is not recommended. Hypoglycemia has been reported following initiation of ENBREL therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.

Please see Prescribing Information and Medication Guide.

INDICATIONS

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used with or without MTX.

ENBREL is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.

IMPORTANT SAFETY INFORMATION AND INDICATIONS: SERIOUS INFECTIONS

Patients treated with ENBREL are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated in the presence of sepsis, active infections, or allergy to ENBREL or its components. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before ENBREL use and periodically during therapy.